Skip to main content

01.12.2015 | Research article | Ausgabe 1/2015 Open Access

BMC Endocrine Disorders 1/2015

Low-dose combined oral contraceptive use is associated with lower bone mineral content variation in adolescents over a 1-year period

BMC Endocrine Disorders > Ausgabe 1/2015
Talita Poli Biason, Tamara Beres Lederer Goldberg, Cilmery Suemi Kurokawa, Maria Regina Moretto, Altamir Santos Teixeira, Hélio Rubens de Carvalho Nunes
Wichtige Hinweise

Competing interest

The authors declare that they have no competing interests.

Authors’ contribution

TPB, TBG, CSK, MRM have equal responsibility in this study. AST: radiologist of the study. HR deCN: statistical consultant. All authors read and approved the final manuscript.



Low-dose combined oral contraceptives (COCs) can interfere with bone mass acquisition during adolescence. This study aimed to evaluate bone mineral density (BMD) and bone mineral content (BMC) in female adolescents taking a standard low-dose COC (ethinylestradiol 20 μg/desogestrel 150 μg) over a 1-year period and to compare their data with those of healthy adolescents from the same age group not taking COCs.


This was a non-randomized parallel-control study with a 1-year follow-up. Sixty-seven adolescents aged from 12 to 19 years, divided into COC users (n = 41) taking 20 μg ethinylestradiol/150 μg desogestrel and COC non-user controls (n = 26), were evaluated by bone densitometry examinations at baseline and after 12 months. Comparisons between the groups at the study onset were performed using the Mann–Whitney test with the significance level fixed at 5% or p < 0.05. Comparisons between the groups at the study onset and after 12 months were based on variations in the median percentages for bone mass variables.


The COC users presented with low bone mass acquisition in the lumbar spine, and had BMD and BMC median variations of 2.07% and +1.57%, respectively, between the measurements at baseline and 12 months. The control group had median variations of +12.16% and +16.84% for BMD and BMC, respectively, over the same period. The total body BMD and BMC showed similar evolutions during the study in both groups. Statistical significance (p < 0.05) was seen for the BMC percentage variation between COC users and non-users.


Use of a low-dose COC (ethinylestradiol 20 μg/desogestrel 150 μg) was associated with lower bone mass acquisition in adolescents during the study period.

Trial registration

Registry Number, RBR-5h9b3c.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

BMC Endocrine Disorders 1/2015 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

23.10.2020 | COVID-19 | Podcast | Nachrichten

Wie SARS-CoV-2 den Nerven gefährlich wird

Mit Prof. Peter Berlit über neurologische Aspekte von COVID-19

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin